Ongoing research aims to better understand the mechanisms of resistance to BRAF inhibitors and develop new therapeutic strategies. Advances in precision medicine and the integration of genomic data into clinical practice hold promise for more personalized and effective treatments. Additionally, novel combination therapies and next-generation inhibitors are being investigated to provide better outcomes for patients with BRAF-mutant cancers.
